Guangzhou Hanfang Pharmaceutical Co Ltd Launches LiposomeGrade Egg Yolk Lecithin

Domestically developed injection-grade product breaks foreign supply monopolies, with full international regulatory certifications for global pharmaceutical clients

Guangzhou, China – 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading Chinese manufacturer of high-end pharmaceutical lipid excipients, today announced the global launch of its injection-grade egg yolk lecithin tailored for liposome drug delivery applications. The product is developed to address the long-standing supply gap of high-purity liposome-grade egg yolk lecithin for global pharmaceutical enterprises, with core features including consistent emulsification performance, low impurity levels, and full compliance with international pharmacopeia standards. This launch aims to provide reliable, cost-effective domestic alternative solutions for global biopharmaceutical clients, further expanding the company’s footprint in the global high-end pharmaceutical excipient market.

Core Technical Advantages of the Liposome-Grade Egg Yolk Lecithin

The product delivers three core technical strengths to meet global pharmaceutical client requirements:
1. High Purity and Stable Performance: Produced via the proprietary integrated green extraction process of supercritical CO₂ extraction, membrane separation, and chromatography separation, the product achieves over 98% purity with extremely low residual solvent and impurity content, ensuring consistent emulsification and membrane-forming performance for liposome formulations.
2. Domestic Supply Breakthrough: As the first domestically developed injection-grade egg yolk lecithin in China, the product has broken long-term foreign monopolies in the high-end pharmaceutical lipid excipient sector, lifting the domestic localization rate of related products from 10% to 90% to ensure stable supply for global clients.
3. Liposome-Specific Optimization: The product is specially adjusted for liposome membrane material applications, with controllable phospholipid composition to meet the requirements of different liposome drug scenarios, including oncology targeted therapy, vaccine delivery, and advanced parenteral preparations.

Global Compliance and Certifications

To meet global market access requirements, the injection-grade egg yolk lecithin has obtained multiple international regulatory certifications, including EU CEP certification, US FDA US-DMF filing, Mexico Cofepris approval, and India DCGI registration. The product fully complies with the quality standards of the European Pharmacopoeia, US Pharmacopeia, and Chinese Pharmacopoeia, and is eligible for export to more than 30 countries and regions worldwide.

Supply and Customization Services

The liposome-grade egg yolk lecithin is now available for global pre-orders through the company’s official website and authorized global distributors, with mass production starting in June 2026. The company also provides customized technical support and product adjustment services for global pharmaceutical enterprises and research institutions, to meet the specific requirements of different liposome drug development projects.

Executive Statement

"The launch of our liposome-grade egg yolk lecithin marks a key milestone in our mission to break foreign monopolies in high-end pharmaceutical excipients," said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited. "We are committed to providing global pharmaceutical clients with reliable, high-quality domestic alternative solutions to support the development of advanced drug delivery systems."

Industry Context and Future Plans

Driven by the growing global demand for targeted drug delivery systems, especially in oncology and vaccine development, the demand for high-purity liposome-grade pharmaceutical excipients has continued to rise in recent years. Guangzhou Hanfang Pharmaceutical’s new product launch responds to this industry trend, providing a stable supply option for global pharmaceutical clients. Looking ahead, the company will continue to invest in R&D of high-end pharmaceutical lipid excipients, optimize the production process of liposome-grade egg yolk lecithin, and expand its global production capacity to meet growing international demand, while improving its global sales and service network to provide localized technical support for more clients.

Company Overview

Guangzhou Hanfang Pharmaceutical Company Limited was founded in 1998, a state-owned pharmaceutical enterprise under the GPHG Group, focusing on the R&D, production, and sales of high-end pharmaceutical lipid excipients, characteristic oncology API, and health products. The company is a national-level specialized and sophisticated "little giant" enterprise, with a national engineering research center for traditional Chinese medicine pharmaceutical process technology and new drug development, as well as a provincial key laboratory for pharmaceutical lipids. It has served more than 1000 clients worldwide, with products exported to over 30 countries and regions. The company’s mission is to achieve technological self-reliance, break "chokepoint" technical bottlenecks, and ensure the security of the global pharmaceutical supply chain. More information is available at http://byshanhanfang.com/.

FAQ

Q: What are the main applications of Guangzhou Hanfang’s egg yolk lecithin?
A: The product is mainly used as an emulsifier, solubilizer, and liposome membrane material for injection-grade liposome drug formulations, including oncology targeted therapies, vaccine delivery systems, and other advanced parenteral preparations.

Q: Does Guangzhou Hanfang’s egg yolk lecithin meet international pharmaceutical standards?
A: Yes, the product has obtained EU CEP certification, US FDA US-DMF filing, Mexico Cofepris approval, and India DCGI registration, and complies with the quality requirements of the European Pharmacopoeia, US Pharmacopeia, and Chinese Pharmacopoeia.

Q: Can Guangzhou Hanfang provide customized egg yolk lecithin for specific liposome development projects?
A: Yes, the company provides customized product adjustment and technical support services for global pharmaceutical enterprises and research institutions to meet the specific requirements of different liposome drug development scenarios.

Contact Us

Official Website: https://byshanhanfang.com/
Factory Address: No.8 Wenquan Avenue, Conghua District, Guangzhou, Guangdong, China